UA123199C2 - Фармацевтична комбінація, яка містить сполуку, націлену на cd33, та епігенетичний фактор - Google Patents

Фармацевтична комбінація, яка містить сполуку, націлену на cd33, та епігенетичний фактор

Info

Publication number
UA123199C2
UA123199C2 UAA201600619A UAA201600619A UA123199C2 UA 123199 C2 UA123199 C2 UA 123199C2 UA A201600619 A UAA201600619 A UA A201600619A UA A201600619 A UAA201600619 A UA A201600619A UA 123199 C2 UA123199 C2 UA 123199C2
Authority
UA
Ukraine
Prior art keywords
combination
treatment
myeloid leukemia
compounds targeting
epigenetic factors
Prior art date
Application number
UAA201600619A
Other languages
English (en)
Inventor
Роланд Б. Вальтер
Маріон Субклеве
Марион Субклеве
Крістіна Крупка
Кристина Крупка
Original Assignee
Амген Інк.
Амген Инк.
Амген Рісьорч (Мюнхен) Гмбх
Амген Рисёрч (Мюнхен) Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Інк., Амген Инк., Амген Рісьорч (Мюнхен) Гмбх, Амген Рисёрч (Мюнхен) Гмбх filed Critical Амген Інк.
Publication of UA123199C2 publication Critical patent/UA123199C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Винахід стосується фармацевтичної комбінації, що включає націлену на CD33 сполуку та епігенетичний фактор, у якій націлена на CD33 сполука являє собою конструкт біспецифічного антитіла, що містить перший домен специфічного зв'язування CD33 та другий домен специфічного зв'язування CD3; а епігенетичний фактор являє собою гідроксисечовину, причому епігенетичний фактор вводиться перед введенням націленої на CD33 сполуки.
UAA201600619A 2013-09-13 2014-09-15 Фармацевтична комбінація, яка містить сполуку, націлену на cd33, та епігенетичний фактор UA123199C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361877714P 2013-09-13 2013-09-13
PCT/EP2014/069575 WO2015036583A2 (en) 2013-09-13 2014-09-15 Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia

Publications (1)

Publication Number Publication Date
UA123199C2 true UA123199C2 (uk) 2021-03-03

Family

ID=51690351

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201600619A UA123199C2 (uk) 2013-09-13 2014-09-15 Фармацевтична комбінація, яка містить сполуку, націлену на cd33, та епігенетичний фактор

Country Status (28)

Country Link
US (1) US10933132B2 (uk)
EP (1) EP3043794B1 (uk)
JP (1) JP6530409B2 (uk)
KR (1) KR102366470B1 (uk)
CN (2) CN111888474A (uk)
AP (1) AP2016009132A0 (uk)
AR (1) AR097648A1 (uk)
AU (2) AU2014320246B2 (uk)
CA (1) CA2923354C (uk)
CL (1) CL2016000564A1 (uk)
DK (1) DK3043794T3 (uk)
EA (1) EA036476B1 (uk)
HK (1) HK1225975A1 (uk)
HU (1) HUE056867T2 (uk)
IL (1) IL278527B (uk)
JO (1) JO3597B1 (uk)
LT (1) LT3043794T (uk)
MA (2) MA46164B1 (uk)
MX (1) MX2016003197A (uk)
MY (1) MY185611A (uk)
NZ (1) NZ716448A (uk)
PH (1) PH12016500434B1 (uk)
SG (2) SG11201600671QA (uk)
SI (1) SI3043794T1 (uk)
TW (1) TWI688401B (uk)
UA (1) UA123199C2 (uk)
WO (1) WO2015036583A2 (uk)
ZA (1) ZA201600528B (uk)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
US10738118B2 (en) * 2015-05-29 2020-08-11 Amphivena Therapeutics, Inc. Methods of using bispecific CD33 and CD3 binding proteins
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
JP6945532B2 (ja) * 2015-12-16 2021-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 改善された組換え体作製方法
TWI797073B (zh) * 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JOP20170091B1 (ar) * 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
PT3600419T (pt) * 2017-03-20 2023-11-16 Vaccinex Inc Tratamento do cancro com um anticorpo semaforina-4d em combinação com um agente modulador epigenético
KR102090407B1 (ko) * 2017-11-24 2020-03-17 충북대학교 산학협력단 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물
WO2019103531A1 (ko) * 2017-11-24 2019-05-31 충북대학교 산학협력단 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물
WO2019108789A1 (en) 2017-11-29 2019-06-06 The Trustees Of Columbia University In The City Of New York Combination therapy of lymphoma
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
MX2021001221A (es) * 2018-07-30 2021-06-23 Amgen Res Munich Gmbh Administración prolongada de un constructo de anticuerpo biespecífico que se une a cd33 y cd3.
US20220098613A1 (en) 2018-09-12 2022-03-31 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
CN113045664B (zh) 2019-11-28 2023-05-12 尚健单抗（北京）生物技术有限公司 一种分离的结合抗原axl的蛋白及其用途
US20230146121A1 (en) 2019-12-09 2023-05-11 Chigenovo Co., Ltd. Use of cyp4v2 and rdcvf in the manufacture of medicament
CN112079934B (zh) 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
AU2020418199B2 (en) 2020-01-02 2024-06-13 Ningbo T-Maximum Biopharmaceuticals Co., Ltd. Modified immune effector cell and preparation method therefor
CN113481165B (zh) * 2020-07-16 2022-06-03 山东博安生物技术股份有限公司 分泌双特异性t细胞衔接子的car-t及治疗实体肿瘤的应用
CN111733174B (zh) 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
TW202222840A (zh) 2020-12-11 2022-06-16 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
KR20230147616A (ko) 2021-01-11 2023-10-23 스타맵 바이오로직스 (쑤저우) 씨오., 엘티디 황색포도상구균 α-독소를 표적으로 하는 항원 결합단백질 및 이의 응용
AU2022207557A1 (en) 2021-01-13 2023-07-06 Huabo Biopharm (Shanghai) Co., Ltd. Cd73-binding protein and use thereof
CN112630438B (zh) * 2021-03-08 2021-06-22 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查髓系疾病及检测免疫检查点的应用
CN117062833A (zh) 2021-03-22 2023-11-14 星济生物(苏州)有限公司 靶向肺炎链球菌溶血素的抗原结合蛋白及其用途
US20240182562A1 (en) 2021-04-02 2024-06-06 Oricell Therapeutics Co., Ltd Cldn18.2 antigen-binding protein and use thereof
CN113533729A (zh) * 2021-06-15 2021-10-22 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
CN115612674A (zh) 2021-07-14 2023-01-17 上海荣瑞医药科技有限公司 一种溶瘤病毒及其用途
CN113461821B (zh) * 2021-09-03 2021-12-28 苏州近岸蛋白质科技股份有限公司 抗cd3人源化抗体
CN114908087B (zh) * 2022-05-07 2024-01-23 四川大学华西医院 一种长循环肾靶向细胞外囊泡的构建及其应用
CN118221826A (zh) * 2024-04-25 2024-06-21 北京绿竹生物技术股份有限公司 一种结合人cd33和cd3的双特异性抗体

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ES2198414T3 (es) 1992-10-23 2004-02-01 Immunex Corporation Procedimientos para preparar proteinas oligomericas solubles.
JP3810791B2 (ja) 1993-09-10 2006-08-16 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 緑色蛍光タンパク質の使用
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
EP1015872B1 (en) 1996-12-12 2005-03-02 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
CA2324648C (en) 1998-03-27 2013-02-26 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
IL138857A0 (en) 1998-04-21 2001-10-31 Micromet Ges For Biomedizinisc Cd19xcd3 specific polypeptides and uses thereof
US20050025823A1 (en) * 2003-07-29 2005-02-03 Fong Andy A.T. Methods of use of herbal compositions
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
CA2625440C (en) 2005-10-11 2023-06-13 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
ES2695047T3 (es) 2007-04-03 2018-12-28 Amgen Research (Munich) Gmbh Dominio de unión específico entre especies
UA112062C2 (uk) * 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
HUE056867T2 (hu) 2022-03-28
JP2016536341A (ja) 2016-11-24
CL2016000564A1 (es) 2017-03-24
PH12016500434A1 (en) 2016-05-16
PH12016500434B1 (en) 2016-05-16
CA2923354A1 (en) 2015-03-19
MX2016003197A (es) 2016-06-02
AU2020202641A1 (en) 2020-05-14
CN111888474A (zh) 2020-11-06
SG11201600671QA (en) 2016-02-26
WO2015036583A2 (en) 2015-03-19
MY185611A (en) 2021-05-25
JO3597B1 (ar) 2020-07-05
CA2923354C (en) 2022-11-29
SG10201801777YA (en) 2018-04-27
AU2014320246B2 (en) 2020-01-23
MA38898A1 (fr) 2018-01-31
US10933132B2 (en) 2021-03-02
AU2014320246A1 (en) 2016-02-18
TW201605473A (zh) 2016-02-16
CN105764505A (zh) 2016-07-13
LT3043794T (lt) 2021-10-25
EP3043794B1 (en) 2021-09-01
TWI688401B (zh) 2020-03-21
JP6530409B2 (ja) 2019-06-12
KR102366470B1 (ko) 2022-02-24
WO2015036583A3 (en) 2015-07-02
NZ716448A (en) 2022-02-25
HK1225975A1 (zh) 2017-09-22
MA46164A1 (fr) 2020-12-31
US20160317657A1 (en) 2016-11-03
AP2016009132A0 (en) 2016-04-30
EA201690485A1 (ru) 2016-08-31
IL278527B (en) 2022-07-01
DK3043794T3 (da) 2021-11-15
AR097648A1 (es) 2016-04-06
EA036476B1 (ru) 2020-11-13
IL278527A (uk) 2020-12-31
SI3043794T1 (sl) 2021-11-30
ZA201600528B (en) 2021-06-30
MA46164B1 (fr) 2021-04-30
EP3043794A2 (en) 2016-07-20
KR20160058120A (ko) 2016-05-24

Similar Documents

Publication Publication Date Title
UA123199C2 (uk) Фармацевтична комбінація, яка містить сполуку, націлену на cd33, та епігенетичний фактор
CY1123236T1 (el) Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3
CY1124993T1 (el) Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20
CY1122478T1 (el) Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη
IL268369A (en) Anti-CD3 antibodies, bispecific-antigen-binding compounds that bind CD3 and CD20, and their uses
EA201690443A1 (ru) Биспецифические моновалентные диатела, которые способны связываться с cd123 и cd3, и их применения
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
NZ707831A (en) Agents for treatment of claudin expressing cancer diseases
MX2020010953A (es) Construcciones de union a antigenos biespecificas dirigidas a her2.
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
CL2015002223A1 (es) Objetivo terapéutico y diagnostico.
EA201691858A1 (ru) Композиции антител для лечения опухолей
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
EA201790060A1 (ru) Биспецифические cd33- и cd3-связывающие белки
DK3645565T3 (da) Bispecifikke antistoffer mod ROR1 og CD3
EA201890175A1 (ru) Антитела к cd40
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
EA202090303A2 (ru) Композиции антител для лечения опухолей
NZ748133A (en) Agents for treatment of claudin expressing cancer diseases